Canine Red Eye Elizabeth Barfield Laminack, DVM; Kathern Myrna, DVM, MS; and Phillip Anthony Moore, DVM, Diplomate ACVO
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
12 Retina Gabriele K
299 12 Retina Gabriele K. Lang and Gerhard K. Lang 12.1 Basic Knowledge The retina is the innermost of three successive layers of the globe. It comprises two parts: ❖ A photoreceptive part (pars optica retinae), comprising the first nine of the 10 layers listed below. ❖ A nonreceptive part (pars caeca retinae) forming the epithelium of the cil- iary body and iris. The pars optica retinae merges with the pars ceca retinae at the ora serrata. Embryology: The retina develops from a diverticulum of the forebrain (proen- cephalon). Optic vesicles develop which then invaginate to form a double- walled bowl, the optic cup. The outer wall becomes the pigment epithelium, and the inner wall later differentiates into the nine layers of the retina. The retina remains linked to the forebrain throughout life through a structure known as the retinohypothalamic tract. Thickness of the retina (Fig. 12.1) Layers of the retina: Moving inward along the path of incident light, the individual layers of the retina are as follows (Fig. 12.2): 1. Inner limiting membrane (glial cell fibers separating the retina from the vitreous body). 2. Layer of optic nerve fibers (axons of the third neuron). 3. Layer of ganglion cells (cell nuclei of the multipolar ganglion cells of the third neuron; “data acquisition system”). 4. Inner plexiform layer (synapses between the axons of the second neuron and dendrites of the third neuron). 5. Inner nuclear layer (cell nuclei of the bipolar nerve cells of the second neuron, horizontal cells, and amacrine cells). 6. Outer plexiform layer (synapses between the axons of the first neuron and dendrites of the second neuron). -
Low Level Light Therapy for the Treatment of Recalcitrant Chalazia: a Sample Case Summary
Clinical Ophthalmology Dovepress open access to scientific and medical research Open Access Full Text Article ORIGINAL RESEARCH Low level light therapy for the treatment of recalcitrant chalazia: a sample case summary This article was published in the following Dove Press journal: Clinical Ophthalmology Karl Stonecipher1 Purpose: To evaluate the effects of low-level light therapy (LLLT) on the resolution of Richard Potvin 2 recalcitrant chalazia. Patients and Methods: This was a single-site retrospective chart review of patients with 1Physicians Protocol, Greensboro, NC, USA; 2Science in Vision, Akron, NY, USA chalazia, all of whom were unresponsive to previous pharmaceutical therapy or surgical intervention, who received a 15 min LLLT treatment in conjunction with a standard phar- maceutical regimen. A second treatment was applied 24 hrs to as late as 2 months if there was no evidence of progression of resolution in appearance. Results: A total of 26 eyes of 22 patients with relevant history and treatment were reviewed, all with a history of prior pharmaceutical treatment for their chalazia. After a single 15 min LLLT treatment, followed by a standard pharmaceutical regimen, 46% of eyes (12/26) showed resolution of their chalazia. Resolution was noted from 3 days to one-month post- treatment. With a second treatment, the chalazia resolved in 92% of eyes (24/26). Only two For personal use only. eyes of the 26 (8%) required incision and curettage after LLLT treatment. Conclusion: The use of LLLT for the treatment of recalcitrant chalazia appears to be beneficial in patients who have failed topical and/or systemic therapy, significantly reducing the likelihood of requiring surgical intervention. -
Differentiate Red Eye Disorders
Introduction DIFFERENTIATE RED EYE DISORDERS • Needs immediate treatment • Needs treatment within a few days • Does not require treatment Introduction SUBJECTIVE EYE COMPLAINTS • Decreased vision • Pain • Redness Characterize the complaint through history and exam. Introduction TYPES OF RED EYE DISORDERS • Mechanical trauma • Chemical trauma • Inflammation/infection Introduction ETIOLOGIES OF RED EYE 1. Chemical injury 2. Angle-closure glaucoma 3. Ocular foreign body 4. Corneal abrasion 5. Uveitis 6. Conjunctivitis 7. Ocular surface disease 8. Subconjunctival hemorrhage Evaluation RED EYE: POSSIBLE CAUSES • Trauma • Chemicals • Infection • Allergy • Systemic conditions Evaluation RED EYE: CAUSE AND EFFECT Symptom Cause Itching Allergy Burning Lid disorders, dry eye Foreign body sensation Foreign body, corneal abrasion Localized lid tenderness Hordeolum, chalazion Evaluation RED EYE: CAUSE AND EFFECT (Continued) Symptom Cause Deep, intense pain Corneal abrasions, scleritis, iritis, acute glaucoma, sinusitis, etc. Photophobia Corneal abrasions, iritis, acute glaucoma Halo vision Corneal edema (acute glaucoma, uveitis) Evaluation Equipment needed to evaluate red eye Evaluation Refer red eye with vision loss to ophthalmologist for evaluation Evaluation RED EYE DISORDERS: AN ANATOMIC APPROACH • Face • Adnexa – Orbital area – Lids – Ocular movements • Globe – Conjunctiva, sclera – Anterior chamber (using slit lamp if possible) – Intraocular pressure Disorders of the Ocular Adnexa Disorders of the Ocular Adnexa Hordeolum Disorders of the Ocular -
The Effect of Topical Beta-Adrenoceptor Blocking Agents on Pulsatile Ocular Blood Flow
THE EFFECT OF TOPICAL BETA-ADRENOCEPTOR BLOCKING AGENTS ON PULSATILE OCULAR BLOOD FLOW C. D. MORSMAN, M. E. BOSEM, M. LUSKY and R. N. WEINREB San Diego, California SUMMARY factors (e.g. hypertension, diabetes, peripheral Thirty-three ocular hypertensive patients (21 with vascular disease and vasospasm) to the vascular primary open angle glaucoma and 12 glaucoma system suggest that blood flow in the optic nerve suspects) were randomly assigned to receive either head and retina may be altered in glaucoma.4 Of the timolol, levobunolol or betaxolol in one eye. Pulsatile various vascular beds within the posterior segment, ocular blood flow (POBF) was measured before the choroidal circulation is of particular interest since treatment (baseline) and 2 hours after drop adminis it provides the major contribution to the blood flow tration. After 1 week of regular twice-daily dosage, of the optic nerve at the level of the lamina cribrosa.5 POBF was measured again both immediately before Beta-2 adrenergic receptors have been demon and 2 hours after drop instillation. All measurements strated in human optic nerve,6 as well as in choroidal were made by an investigator masked to treatment. and retinal blood vessels.7 Blockade of these POBF increased by 11% (p = 0.09) at week 0 after receptors can cause vasoconstrictionS which could levobunolol administration, and by 22% (p = 0.20) at adversely affect visual function if adequate concen week 1 before drop administration compared with trations of the drug diffused into the posterior baseline. It dropped by 23% and 25% (p = 0.04 and segment of the eye or were absorbed systemically. -
Peripapillary Retinal Vascular Involvement in Early Post-COVID-19 Patients
Journal of Clinical Medicine Article Peripapillary Retinal Vascular Involvement in Early Post-COVID-19 Patients 1,2, 1,2, 1,2, Alfonso Savastano y , Emanuele Crincoli y , Maria Cristina Savastano * , Saad Younis 3, Gloria Gambini 1,2, Umberto De Vico 1,2 , Grazia Maria Cozzupoli 1,2 , Carola Culiersi 1,2 , Stanislao Rizzo 1,2,4 and Gemelli Against COVID-19 Post-Acute Care Study Group 2 1 Ophthalmology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00196 Rome, Italy; [email protected] (A.S.); [email protected] (E.C.); [email protected] (G.G.); [email protected] (U.D.V.); [email protected] (G.M.C.); [email protected] (C.C.); [email protected] (S.R.) 2 Department of Ophthalmology, Catholic University of “Sacro Cuore”, 00168 Rome, Italy 3 Department of Ophthalmology, Western Eye Hospital, Imperial College Healthcare NHS Trust, London NW1 5QH, UK; [email protected] 4 Neuroscience Institute, Consiglio Nazionale delle Ricerche, Istituto di Neuroscienze, 56124 Pisa, Italy * Correspondence: [email protected]; Tel.: +39-063-015-4928 These authors contributed equally to this work. y Received: 5 August 2020; Accepted: 3 September 2020; Published: 8 September 2020 Abstract: The ability of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-20s) to cause multi-organ ischemia and coronavirus-induced posterior segment eye diseases in mammals gave concern about potential sight-threatening ischemia in post coronavirus disease 2019 patients. The radial peripapillary capillary plexus (RPCP) is a sensitive target due to the important role in the vascular supply of the peripapillary retinal nerve fiber layer (RNFL). -
RETINAL DISORDERS Eye63 (1)
RETINAL DISORDERS Eye63 (1) Retinal Disorders Last updated: May 9, 2019 CENTRAL RETINAL ARTERY OCCLUSION (CRAO) ............................................................................... 1 Pathophysiology & Ophthalmoscopy ............................................................................................... 1 Etiology ............................................................................................................................................ 2 Clinical Features ............................................................................................................................... 2 Diagnosis .......................................................................................................................................... 2 Treatment ......................................................................................................................................... 2 BRANCH RETINAL ARTERY OCCLUSION ................................................................................................ 3 CENTRAL RETINAL VEIN OCCLUSION (CRVO) ..................................................................................... 3 Pathophysiology & Etiology ............................................................................................................ 3 Clinical Features ............................................................................................................................... 3 Diagnosis ......................................................................................................................................... -
Cranial Nerve Palsy
Cranial Nerve Palsy What is a cranial nerve? Cranial nerves are nerves that lead directly from the brain to parts of our head, face, and trunk. There are 12 pairs of cranial nerves and some are involved in special senses (sight, smell, hearing, taste, feeling) while others control muscles and glands. Which cranial nerves pertain to the eyes? The second cranial nerve is called the optic nerve. It sends visual information from the eye to the brain. The third cranial nerve is called the oculomotor nerve. It is involved with eye movement, eyelid movement, and the function of the pupil and lens inside the eye. The fourth cranial nerve is called the trochlear nerve and the sixth cranial nerve is called the abducens nerve. They each innervate an eye muscle involved in eye movement. The fifth cranial nerve is called the trigeminal nerve. It provides facial touch sensation (including sensation on the eye). What is a cranial nerve palsy? A palsy is a lack of function of a nerve. A cranial nerve palsy may cause a complete or partial weakness or paralysis of the areas served by the affected nerve. In the case of a cranial nerve that has multiple functions (such as the oculomotor nerve), it is possible for a palsy to affect all of the various functions or only some of the functions of that nerve. What are some causes of a cranial nerve palsy? A cranial nerve palsy can occur due to a variety of causes. It can be congenital (present at birth), traumatic, or due to blood vessel disease (hypertension, diabetes, strokes, aneurysms, etc). -
Epiphora During the First Year of Life
Eye (1991) 5, 596--600 Epiphora During the First Year of Life C. J. MACEWEN and J. D. H. YOUNG Dundee Summary A cohort of 4,792 infants was observed in order to determine the incidence and natu ral history of epiphora during the first year of life. Evidence of defective lacrimal drainage was present in 964 (20%) at some time during the year. 9S�/o became symp tomatic during the first month of life. Spontaneous remission occurred throughout the year and 96% had resolved before the age of one. This study provides no evidence to support probing before the age of one year. Infants with epiphora are a common problem haps the most reliable estimate of the inci in clinical ophthalmology. It is generally dence is 6%. This comes from a follow-up accepted that the condition is the result of a study of 200 consecutive, unselected newborn congenital abnormality of the lacrimal drain infants.7 age system, in the form of a membranous Information on the rate of spontaneous obstruction at the lower end of the naso-lac remission is also limited. The studies that are rimal duct (NLD). I In addition it is recognised available were based on small clinic popula that there is a high rate of spontaneous resol tions, referred for treatment of their epiphora ution.2•3 However, despite it's frequency, rela and probing was usually undertaken in a tively little is known about the incidence or number of cases before the end of the year.2,3 natural history of epiphora in young children. -
Special Considerations in Cataract Surgery: Five Cornea Challenges
Clinical Update EXTRA CONTENT AVAILABLE CATARACT Special Considerations in Cataract Surgery: Five Cornea Challenges by linda roach, contributing writer interviewing preston h. blomquist, md, rosa a. braga-mele, md, kimberly a. drenser, md, phd, herbert e. kaufman, md, marguerite mcdonald, md, and roger f. steinert, md s the most common surgical choices, said Marguerite McDonald, IOL Selection procedure in ophthalmol- MD, of Lynbrook, N.Y. The device en- ogy, replacement of a cloudy ables the surgeon to directly measure 1 crystalline lens with an the eye’s aphakic refractive power in intraocular lens (IOL) usu- the operating room. Aally presents the ophthalmologist with Using intraoperative aberrometry is familiar sets of surgical routines. But becoming more commonplace, as “it what about those cases that involve may help in achieving more accuracy comorbidities or other complicating with IOL power selection,” Dr. Mc- factors? Donald said. Several experts shared their per- Tips on IOL selection. The chosen spectives on approaching out-of-the- IOL should be shaped to neutralize After an off-center LASIK procedure ordinary cataract surgeries in ways spherical aberrations, said Rosa A. such as this, the irregularity of the that offer the best chance at optimiz- Braga-Mele, MD, at the University of corneal topography indicates that a ing patient outcomes. This month, Toronto. “In anybody who has had multifocal IOL should be avoided. here’s a look at five challenges involv- myopic LASIK or PRK, I think it’s very ing the cornea. important to use a negatively aspheric prior to cataract surgery. 2) A dysfunc- IOL, because these patients have more tional, unstable tear film will affect the Challenge: Prior Refractive Surgery positively aberrant corneas. -
Novel Anterior Segment Phenotypes Resulting from Forkhead Gene Alterations: Evidence for Cross-Species Conservation of Function
Novel Anterior Segment Phenotypes Resulting from Forkhead Gene Alterations: Evidence for Cross-Species Conservation of Function Ordan J. Lehmann,1 Stephen Tuft,2 Glen Brice,3 Richard Smith,4 Åsa Blixt,5 Rachel Bell,3 Bengt Johansson,6 Tim Jordan,1 Roger A. Hitchings,2 Peng T. Khaw,2 Simon W. M. John,4 Peter Carlsson,5 and Shomi S. Bhattacharya1 PURPOSE. Mutations in murine and human versions of an ances- cause it may affect the clinical management of certain trally related gene usually result in similar phenotypes. How- glaucoma subtypes and lead to excessive treatment. The ever, interspecies differences exist, and in the case of two FOXC1 and Foxe3 data, taken together with the novel ocular forkhead transcription factor genes (FOXC1 and FOXC2), phenotypes of FOXC2 mutations, highlight the remarkable these differences include corneal or anterior segment pheno- cross-species conservation of function among forkhead genes. types, respectively. This study was undertaken to determine (Invest Ophthalmol Vis Sci. 2003;44:2627–2633) DOI:10.1167/ whether such discrepancies provide an opportunity for iden- iovs.02-0609 tifying novel human–murine ocular phenotypes. METHODS. Four pedigrees with early-onset glaucoma pheno- types secondary to segmental chromosomal duplications or ecognition that mutations in orthologous genes frequently deletions encompassing FOXC1 and 18 individuals from 9 Rcause similar phenotypes has allowed the field of compar- FOXC2 mutation pedigrees underwent detailed ocular pheno- ative genetics to contribute to the understanding of human typing. Subsequently, mice with mutations in Foxc1 or a re- disease. As the human, murine, and Drosophila PAX6 mutants lated forkhead gene, Foxe3, were assessed for features of the (aniridia, Small eye, and eyeless) demonstrate, genotypic con- human phenotypes. -
Use of Emulsions for Intra- and Periocular Injection
(19) & (11) EP 1 611 879 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 9/107 (2006.01) 12.08.2009 Bulletin 2009/33 (21) Application number: 04291684.1 (22) Date of filing: 02.07.2004 (54) Use of emulsions for intra- and periocular injection Verwendung von Emulsionen zur intra- und periocularen Injection Utilisation des émulsions pour injection intra- et périoculaire. (84) Designated Contracting States: (74) Representative: de Mareüil-Villette, Caroline et al AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Cabinet Plasseraud HU IE IT LI LU MC NL PL PT RO SE SI SK TR 52 rue de la Victoire 75440 Paris Cedex 09 (FR) (43) Date of publication of application: 04.01.2006 Bulletin 2006/01 (56) References cited: EP-A- 0 521 799 EP-A- 1 020 194 (73) Proprietors: WO-A-02/09667 WO-A-93/18852 • Novagali Pharma S.A. WO-A-94/05298 WO-A-03/053405 91000 Evry (FR) US-A- 5 632 984 • CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) • KLANG S H ET AL: "PHYSICOCHEMICAL 75016 Paris (FR) CHARACTERIAZATION AND ACUTE TOXICITY • INSTITUT NATIONAL DE LA SANTE ET DE LA EVALUATION OF A POSITIVELY-CHARGED RECHERCHE MEDICALE (INSERM) SUBMICRON EMULSION VEHICLE" JOURNAL 75013 Paris (FR) OF PHARMACY AND PHARMACOLOGY, • YISSUM RESEARCH DEVELOPMENT COMPANY LONDON, GB, vol. 46, no. 12, December 1994 OF THE HEBREW UNIVERSITY OF JERUSALEM (1994-12), pages 986-993, XP008005426 ISSN: 91390 Jerusalem (IL) 0022-3573 • KLANG S ET AL: "INFLUENCE OF EMULSION (72) Inventors: DROPLET SURFACE CHARGE ON • Rabinovich-Guilatt, Laura INDOMETHACIN OCULAR TISSUE 75015 Paris (FR) DISTRIBUTION" PHARMACEUTICAL • De Kozak, Yvonne DEVELOPMENT AND TECHNOLOGY, NEW 75013 Paris (FR) YORK, NY, US, vol. -
Olivia Steinberg ICO Primary Care/Ocular Disease Resident American Academy of Optometry Residents Day Submission
Olivia Steinberg ICO Primary Care/Ocular Disease Resident American Academy of Optometry Residents Day Submission The use of oral doxycycline and vitamin C in the management of acute corneal hydrops: a case comparison Abstract- We compare two patients presenting to clinic with an uncommon complication of keratoconus, acute corneal hydrops. Management of the patients differs. One heals quickly, while the other has a delayed course to resolution. I. Case A a. Demographics: 40 yo AAM b. Case History i. CC: red eye, tearing, decreased VA x 1 day OS ii. POHx: (+) keratoconus OU iii. PMHx: depression, anxiety, asthma iv. Meds: Albuterol, Ziprasidone v. Scleral CL wearer for approximately 6 months OU vi. Denies any pain OS, denies previous occurrence OU, no complaints OD c. Pertinent Findings i. VA cc (CL’s)- 20/25 OD, 20/200 PH 20/60+2 OS ii. Slit Lamp 1. Inferior corneal thinning and Fleisher ring OD, central scarring OD, 2+ diffuse microcystic edema OS, Descemet’s break OS (photos and anterior segment OCT) 2. 2+ diffuse injection OS 3. D&Q A/C OU iii. Intraocular Pressures: deferred OD due to CL, 9mmHg OS (tonopen) iv. Fundus Exam- unremarkable OU II. Case B a. Demographics: 39 yo AAM b. Case History i. CC: painful, red eye, tearing, decreased VA x 1 day OS ii. POHx: unremarkable iii. PMHx: hypertension iv. Meds: unknown HTN medication v. Wears Soflens toric CL’s OU; reports previous doctor had difficulty achieving proper fit OU; denies diagnosis of keratoconus OU vi. Denies any injury OS, denies previous occurrence OU, no complaints OD c.